Asset Publisher

Draft Provider-Administered Drug Policies

Draft policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.

Provider-administered oncology drugs require that a member’s medical condition meets the policy requirements prior to being given (precertification) unless otherwise specified.

Providers must submit a request through Magellan Rx for pre-service review in order to be approved. If the provider does not receive approval for precertification, the plan will pay no benefits.  

Currently, precertification for these provider-administered drugs is required when administered in a provider’s office, outpatient facility or home health setting; however, this precertification does not apply to inpatient hospital claims at this time.

Note: Coverage is subject to the member's specific benefits. Group-specific benefits will supersede these policies when applicable. Always check eligibility and benefits through your local Blue Plan provider portal or your practice management system to confirm member-specific benefits.

To request a copy of a drug policy, members can contact Customer Service by calling the number on their ID card.

Comment on Draft Oncology Drug Policies

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to draft policies.

Comments are accepted for 45 days from the posting date listed on the draft policy.

Make sure your voice is heard by providing feedback directly to us:

 

  • Send comments and supporting documentation by mail or fax

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-0878

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.

Note: Coverage is subject to the member's specific benefits. Group-specific benefits will supersede these policies when applicable. Always check eligibility and benefits through your local Blue Plan provider portal or your practice management system to confirm member-specific benefits. 

Comment on Draft Drug Policies

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies.

We accept comments for 45 days from the posting date listed on the draft policy.

Make sure your voice is heard by providing feedback directly to us:

Birmingham Service Center 
Attn: Pharmacy Department
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-9576

Policy # Policy Title Print View
-9059 SCIG (immune globulin SQ): Hizentra®, Gammagard Liquid®, Gamunex®-C, Gammaked™, HyQvia®, Cuvitru®, Cutaquig®, Xembify®
-90682 Tecvayli™ (teclistamab-cqyv)
PH-90002 Tocilizumab: Actemra®; Tofidence™; Tyenne®
PH-90017 Benlysta® (belimumab)
PH-90026 Aflibercept: Eylea®; Eylea® HD; Opuviz™; Yesafili™
PH-90052 Alpha-1-Proteinase Inhibitors: Aralast NP®; Glassia®; Prolastin®-C; Zemaira®
PH-90080 Leuprolide Suspension: Lupron Depot®, Lupron Depot-Ped®, Eligard®, Fensolvi®, Camcevi™, Lutrate Depot™, Leuprolide Acetate Depot Ψ(Precertification not required)
PH-90098 Denosumab: Prolia®; Jubbonti®; Xgeva®; Wyost®
PH-90105 Elelyso™ (taliglucerase alfa)
PH-90111 Sandostatin® LAR (octreotide suspension) (Precertification not required)
PH-90114 Eculizumab: Soliris®; Bkemv™
PH-90117 Ustekinumab: Stelara®; Wezlana™; Selarsdi™
PH-90131 Trelstar® (triptorelin) (Precertification not required)
PH-90141 VPRIV® (velaglucerase alfa)
PH-90146 Xolair® (omalizumab)
PH-90181 Visudyne® (verteporfin)
PH-90202 Entyvio® (vedolizumab)
PH-90237 Leukine® (sargramostim)
PH-90242 Aranesp® (darbepoetin alfa)
PH-90243 Epoetin alfa: Epogen®; Procrit®; Retacrit™
PH-90244 Mircera® (methoxy polyethylene glycol-epoetin beta) (Precertification not required)
PH-90284 Exondys 51™ (eteplirsen)
PH-90312 Injectafer® (ferric carboxymaltose injection)
PH-90347 Fasenra® (benralizumab)
PH-90503 Reblozyl® (luspatercept-aamt)
PH-90520 Vyondys 53™ (golodirsen)
PH-90524 Monoferric™ (ferric derisomaltose)
PH-90562 Viltepso™ (viltolarsen)
PH-90591 Evkeeza™ (evinacumab-dgnb)
PH-90593 Amondys 45™  (casimersen)
PH-90614 Saphnelo™ (anifrolumab-fnia)
PH-90633 Xipere® (triamcinolone acetonide injectable suspension)
PH-90635 Dextenza® (dexamethasone insert)
PH-90652 Leqvio® (inclisiran)
PH-90660 Enjaymo™ (sutimlimab-jome)
PH-90672 Zynteglo® (betibeglogene autotemcel)
PH-90674 Spevigo® (spesolimab)
PH-90688 Hemgenix® (etranacogene dezaparvovec-drlb)
PH-90694 Leqembi™ (lecanemab-irmb)
PH-90708 Elfabrio® (pegunigalsidase alfa-iwxj)
PH-9071 Immune Globulins (immunoglobulin): Asceniv™; Alyglo™; Bivigam®; Flebogamma®; Gamunex-C®; Gammagard® Liquid; Gammagard® S/D; Gammaked™; Gammaplex®; Octagam®; Privigen®; Panzyga®
PH-90718 Roctavian® (valoctocogene roxaparvovec-rvox)
PH-90721 Izervay™ (avacincaptad pegol)
PH-90734 Omvoh™ (mirikizumab-mrkz)
PH-90744 Casgevy™ (exagamglogene autotemcel) (Intravenous)
PH-90751 Lenmeldy™ (atidarsagene autotemcel)
PH-90755 Beqvez™ (fidanacogene elaparvovec-dzkt)
PH-9238 Botox® (onabotulinumtoxinA)
PH-9239 Dysport® (abobotulinumtoxinA)
PH-9240 Myobloc® (rimabotulinumtoxinB)
PH-9241 Xeomin® (incobotulinumtoxinA)
PH-9468 Zolgensma® (onasemnogene abeparvovec-xioi)
PH-9527 Vyepti® (eptinezumab-jjmr)
VP-90157 Kyprolis® (carfilzomib)
VP-90274 Imlygic® (talimogene laherparepvec)
VP-90531 Jelmyto® (mitomycin)
VP-90590 Breyanzi® (lisocabtagene maraleucel)
VP-90598 Abecma® (idecabtagene vicleucel)
VP-90663 Carvykti™ (ciltacabtagene autoleucel)
VP-90691 Adstiladrin® (nadofaragene firadenovec-vncg)